Strides Arcolab gets USFDA nod for Benzonatate capsules

The product will be launched immediately in the US market

Strides-Arcolab
Press Trust of India New Delhi
Last Updated : Jul 31 2015 | 2:37 PM IST
Drug firm Strides Arcolab has received approval from the US health regulator for its Benzonatate softgel capsules used for treating cough caused by cold, and other breathing problems such as pneumonia and asthma.

The product will be launched immediately in the US market, Strides Arcolab said in a filing to BSE.

The company has received approval from the United States Food and Drug Administration (USFDA) for Benzonatate softgel capsules in the strengths of 100mg and 200 mg, it added.

Also Read

"According to IMS data, the US market for Benzonatate is approximately USD 41 million," Strides Arcolab said.

The product will be manufactured at the company's oral dosage facility at Bengaluru and marketed by the company in the US, it added.

Shares of Strides Arcolab were trading at Rs 1,272.70 per scrip on BSE, up 1.18 per cent from its previous close.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 31 2015 | 1:42 PM IST

Next Story